-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The first batch of Esomeprazole sodium, which also welcomed the first review, belongs to proton pump inhibitors (PPI), mainly by inhibiting the secretion of H-plus driven by proton pumps in the stomach wall cells, thereby inhibiting the secretion of stomach acid.
The main dosage forms of pyroazole currently listed for sale in China are injections, intestinal tablets and intestinal capsules, of which injections are the most widely used clinically, and public data show that sales of end-use pyroazole in public medical institutions in China in 2019 amounted to 8.907 billion yuan, down 9.37% YoY.
Insight database shows that 16 companies have submitted supplementary applications (including Jiangsu Osaikang) for sodium in injections, and 2 companies have submitted applications for listing under the new registration classification, involving a total of 32 product regulations.
, Osaikang was the first company to submit a supplementary application, and the first to pass a consistency review.
from the Insight database () There are currently six proton pump inhibitors in the domestic market, lanso laazole, vitolazole, omeprazole, Esomeprazole and Epprazole, all available in injection and oral dosage forms.
, however, according to Insight data, all but esomeprazole and vitolazole in this review were not evaluated with injections.
the two PPI reviews with a consistent evaluation, which kicks off the PPI review.